Physician profile
Scott Goldsmith
NPI 1730528266
$180,268.35
in general payments reported to CMS, 2019-2025
16 companies · $14K in 2025
The $14K reported for 2025 was more than what 81% of Hematology (Internal Medicine) providers received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115 · 2020: $99.99 · 2021: $4,908 · 2022: $7,305 · 2023: $58K · 2024: $96K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $120K · Consulting Fee: $34K · Travel and Lodging: $9,617 · Food and Beverage: $4,271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $119,999.00 |
| Consulting Fee | $33,954.00 |
| Travel and Lodging | $9,616.67 |
| Food and Beverage | $4,270.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $129,520.78 | 2022-2025 | Tecvayli, Darzalex, Carvykti |
| Adaptive Biotechnologies Corporation | $20,476.39 | 2022-2024 | Clonoseq |
| E.R. Squibb & Sons, L.L.C. | $17,847.77 | 2023-2025 | Abecma |
| Genzyme Corporation | $7,863.81 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $3,757.50 | 2021-2023 | |
| Celgene Corporation | $279.53 | 2021-2024 | |
| Zimmer Biomet Holdings, INC. | $114.76 | 2019 | |
| Pfizer INC. | $108.60 | 2024-2025 | |
| Amgen INC. | $99.99 | 2020 | |
| Pharmacyclics LLC, An Abbvie Company | $58.00 | 2022-2023 | Imbruvica |
| Biolinerx USA, INC. | $50.00 | 2024 | Aphexda |
| Daiichi Sankyo INC. | $34.56 | 2023-2024 | Vanflyta |
| Glaxosmithkline, LLC. | $31.76 | 2025 | Ojjaara, Blenrep |
| Merck Sharp & Dohme LLC | $24.90 | 2023 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Goldsmith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.